News Summary

Next Gen Diagnostics (NGD), a biotechnology company specializing in automated whole genome sequencing and bioinformatics, has relocated its laboratory to Kendall Square in Cambridge, Massachusetts. This move positions NGD at the center of a prominent life sciences hub, enhancing its R&D capabilities and fostering collaborations with academic and industry partners. NGD’s technology aids in tracking infection transmission in real-time, providing hospitals with actionable reports to improve infection prevention measures. The company’s platform aims to bridge the detection gap in hospital transmissions, empowering healthcare providers to intervene more effectively. This strategic relocation is part of NGD’s broader plan to expand its U.S. presence and commercialization efforts by 2025.